Revvity (RVTY) announced that the FDA has approved the Auto-Pure 2400 liquid handling platform with the T-SPOT.TB test. Initially launched outside the U.S. in 2024, this combination allows laboratories to improve productivity while maintaining clinical performance in latent tuberculosis detection.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVTY:
- Revvity enters agreement with Genomics England for Generation Study collab
- Revvity wins permanent injuction to enforce agreements with Cloud Software Group
- Revvity’s Strong Recurring Revenue and Growth Prospects Justify Buy Rating
- Revvity price target raised to $141 from $137 at Baird
- Revvity price target raised to $145 from $132 at KeyBanc